Biologic therapy in patients receiving salvage treatment

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Biologic response modifiers (BRMs), including recombinant cytokines and hematopoietic growth factors, are increasingly utilized in cancer care.
• These agents aim to treat refractory hematologic malignancies, solid tumors, and therapy-related complications like myelosuppression, thrombocytopenia, and anemia.

Purpose of the Study:

• To review the efficacy and role of biologic response modifiers in treating various cancers and their associated complications.
• To assess the effectiveness of cytokines and hematopoietic growth factors in both primary and salvage therapy settings.

Main Methods:

• Literature review of studies investigating the use of recombinant cytokines and hematopoietic growth factors.
• Analysis of treatment outcomes in patients with hematologic malignancies and solid tumors receiving BRMs.
• Evaluation of BRMs in managing chemotherapy-induced side effects.

Main Results:

• Cytokines show some effectiveness in hematologic malignancies, but durable responses in salvage settings are uncommon.
• In solid tumors like renal cell carcinoma, melanoma, and colorectal cancer, cytokines have a limited role in primary therapy and minimal value in salvage therapy.
• Hematopoietic growth factors (e.g., G-CSF, GM-CSF) and newer agents like interferons and interleukins are valuable in managing complications of malignancy and cancer treatment.

Conclusions:

• Biologic response modifiers offer therapeutic potential, particularly in managing treatment-related toxicities.
• Their role in achieving durable responses for refractory hematologic malignancies and solid tumors, especially in salvage therapy, remains limited.
• Further research may refine the application of these agents in supportive care and specific oncologic settings.